Teva (NYSE: TEVA) EVP Christine Fox sells 21,258 shares in open trade

Rhea-AI Filing Summary

Teva Pharmaceutical Industries EVP Christine Fox, who leads U.S. Commercial operations, reported an open-market sale of 21,258 Ordinary Shares of Teva on April 30, 2026 at a weighted average price of $35.31 per share. The filing notes these shares were sold in multiple trades between $35.28 and $35.33 per share. Following this transaction, Fox directly holds 63,647 Ordinary Shares, which may also be represented by American Depositary Shares, each currently representing one Ordinary Share.

Insider Trade Summary

Net Seller: 21,258 shares ($750,620)

Net Sell 1 txn

Insider Fox Christine

Role EVP, U.S. Commercial

Sold 21,258 shs ($751K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	21,258	$35.31	$751K

Holdings After Transaction: Ordinary Shares — 63,647 shares (Direct, null)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.28 to $35.33, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 21,258 shares Weighted average sale price: $35.31 per share Post-transaction holdings: 63,647 shares +2 more

5 metrics

Shares sold 21,258 shares Open-market sale on April 30, 2026

Weighted average sale price $35.31 per share Ordinary Shares sold by EVP Christine Fox

Post-transaction holdings 63,647 shares Ordinary Shares directly owned after sale

Sale price range $35.28–$35.33 Range of prices across multiple sale trades

ADS to Ordinary Share ratio 1:1 Each ADS currently represents one Ordinary Share

Key Terms

Form 4, open-market sale, American Depositary Shares, weighted average price

4 terms

Form 4 regulatory

"Reported on Form 4 as an insider open-market sale of Ordinary Shares."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open-market sale financial

"The transaction is classified as an open-market sale of 21,258 Ordinary Shares."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

American Depositary Shares financial

"Ordinary Shares may be represented by American Depositary Shares, each representing one Ordinary Share."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

weighted average price financial

"The price reported is a weighted average price based on multiple trades."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fox Christine

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV ISRAEL 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, U.S. Commercial

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	04/30/2026		S		21,258	D	$35.31(2)	63,647	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.28 to $35.33, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

	/s/ Dov Bergwerk as attorney-in-fact for Christine Fox	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Teva (TEVA) report for Christine Fox?

Teva reported that EVP U.S. Commercial Christine Fox executed an open-market sale of 21,258 Ordinary Shares. The sale was reported on Form 4 and reflects a routine insider transaction disclosed to the SEC for transparency and regulatory compliance.

At what price did Christine Fox sell Teva (TEVA) shares?

Christine Fox’s Teva share sale used a weighted average price of $35.31 per share. Footnotes explain the shares were sold in multiple trades, with individual prices ranging from $35.28 to $35.33, and detailed trade breakdowns are available upon request.

How many Teva (TEVA) shares does Christine Fox hold after the sale?

After the reported transaction, Christine Fox directly holds 63,647 Ordinary Shares of Teva. This figure represents her remaining direct equity position as disclosed in the Form 4, giving investors context on her ongoing ownership stake in the company.

What type of security did Christine Fox sell in Teva (TEVA)?

The transaction involved Teva Ordinary Shares, which the filing notes may be represented by American Depositary Shares. Each American Depositary Share currently represents one Ordinary Share, providing investors a clear view of the security class involved in the sale.

Was Christine Fox’s Teva (TEVA) share sale a single trade or multiple trades?

The filing states the reported price is a weighted average, indicating multiple trades were executed. Individual sale prices ranged from $35.28 to $35.33, and the reporting person has committed to provide detailed trade information upon request to interested parties.